HIV Infections Clinical Trial
Official title:
A Phase 1, Single-center, Open-label Study to Evaluate the Pharmacokinetics of Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol (Loestrin) When Co-administered With VH4524184 in Healthy Adult Female Participants
NCT number | NCT06310616 |
Other study ID # | 219888 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | March 6, 2024 |
Est. completion date | May 28, 2024 |
This study aims to assess any impact of VH4524184 on the pharmacokinetic (PK) profile of an ethinyl estradiol (EE) and norethindrone acetate (NEA) containing oral contraceptive (OC) administered to healthy adult female participants.
Status | Recruiting |
Enrollment | 25 |
Est. completion date | May 28, 2024 |
Est. primary completion date | May 28, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Healthy participants 18 to 45 years of age - POCBP with intact ovarian function by medical history and history of regular menstrual cycles for the past 12 - Body weight greater than or equal to (=) 45 kilograms (kg) and Body mass index (BMI) within the range of 18.5 to 32.0 kg/m2 - Female participants of childbearing potential must use approved highly effective non-hormonal forms of birth control. - Capable of giving signed informed consent. Exclusion Criteria: - History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs. - Lymphoma, leukemia, or any malignancy within the past 5 years with some exceptions - Breast cancer or in remission within the past 10 years. - Current or chronic history of liver disease or known hepatic or biliary abnormalities with some exceptions. - Any personal and/or family history of thrombophilia or blood clots - Medical history of cardiac arrhythmias or cardiac disease or a family and personal history of long QT syndrome. - History of seizure(s). - Any known or suspected pre-existing psychiatric condition, including depression, anxiety, and/or insomnia/sleep disturbances. - Subjects with history of drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions will be excluded. - Participant is mentally or legally incapacitated. Prior/Concomitant Therapy • Any warnings and contraindications that apply based on Loestrin prescribing information. Prior/Concurrent Clinical Study Experience - Exposure to more than 4 new investigational products (including long-acting investigational products) within 12 months prior to the first dosing day. - Current enrollment or past participation in another investigational study in which an investigational intervention was administered within the last 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) before signing of consent (or screening) any other clinical study. - Participant has donated or lost blood (>500 millilitres (mL)) or blood products within 2 months (56-day period) prior to Day -1 admission or has donated plasma within 30 days prior to first OC administration. - Current enrollment or past participation in this clinical study. Unwillingness or inability to follow the procedures outlined in the protocol. - Positive Human immunodeficiency virus 1 (HIV-1) antibody test. - Pregnant at screening) or lactating. - POCBP who are unwilling or unable to use an appropriate non-hormonal method of highly effective contraception from at least Day 1 of Treatment Period 1 until 14 days after the last dose of VH4524184. - Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of >7 units for females. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits. - Regular use of known drugs of abuse. |
Country | Name | City | State |
---|---|---|---|
United States | GSK Investigational Site | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
ViiV Healthcare |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the concentration-time curve (AUC) from time zero (pre-dose) to the end of the dosing interval at steady state (AUC0-Tau, ss) of EE and NEA without coadministration with VH4524184 | Blood samples will be collected at indicated timepoint for plasma EE and NEA PK analysis. | On Day 10 | |
Primary | AUC0-Tau, ss of EE and NEA with coadministration with VH4524184 | Blood samples will be collected at indicated timepoint for plasma EE and NEA PK analysis. | On Day 20 | |
Primary | Maximum plasma concentration (Cmax) for EE and NEA without coadministration with VH4524184 | Blood samples will be collected at indicated timepoint for plasma EE and NEA PK analysis. | On Day 10 | |
Primary | Cmax for EE and NEA with coadministration with VH4524184 | Blood samples will be collected at indicated timepoint for plasma EE and NEA PK analysis. | On Day 20 | |
Secondary | Number of participants with adverse events (AEs) and severity of AEs | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. | From Day -28 (Run-In-Period) up to approximately 2 months (Day 28 +/- 3 days) | |
Secondary | Number of participants with AEs leading to discontinuation of study intervention | Throughout the study treatment period (from Day -28 up to Day 20) | ||
Secondary | Change from baseline of liver panel laboratory parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ASP) (International units per liter) | Baseline (Day -28) up to Day 21 | ||
Secondary | Change from baseline of liver panel laboratory parameters: Total bilirubin, Direct bilirubin (Micromoles per liter [umol/L]) | Baseline (Day -28) up to Day 21 | ||
Secondary | Change from baseline of liver panel laboratory parameters: International normalized ratio (INR) (Ratio) | Baseline (Day -28) up to Day 21 | ||
Secondary | Number of participants with maximum toxicity grade increase from baseline of liver panel laboratory parameters: ALT, AST, alkaline phosphatase, total bilirubin, Direct bilirubin, and INR | Baseline (Day -28) up to Day 21 | ||
Secondary | Maximum plasma concentration at steady state (Cmax,ss) for VH4524184 | Blood samples will be collected at indicated timepoint for plasma VH4524184 PK analysis. | On Day 20 | |
Secondary | Time to maximum concentration at steady state (Tmax, ss) during dosing interval for VH4524184 | Blood samples will be collected at indicated timepoint for plasma VH4524184 PK analysis. | On Day 20 | |
Secondary | Area under the concentration-time curve from time zero(pre-dose) to the end of the dosing interval at steady state (AUC0-Tau, ss) for VH4524184 | Blood samples will be collected at indicated timepoint for plasma VH4524184 PK analysis. | On Day 20 | |
Secondary | Trough concentration prior to the next dose (Ctrough) for VH4524184 | Blood samples will be collected at indicated timepoints for plasma VH4524184 PK analysis. | On Day 12, Day 16, and Day 20 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |